"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 2 | 3 | 5 |
| 2004 | 5 | 1 | 6 |
| 2005 | 3 | 4 | 7 |
| 2006 | 4 | 4 | 8 |
| 2007 | 6 | 2 | 8 |
| 2008 | 2 | 3 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 6 | 2 | 8 |
| 2011 | 5 | 2 | 7 |
| 2012 | 4 | 4 | 8 |
| 2013 | 5 | 4 | 9 |
| 2014 | 4 | 3 | 7 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 5 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 3 | 6 |
| 2020 | 5 | 6 | 11 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis. J Drugs Dermatol. 2022 Oct 01; 21(10):1133-1134.
-
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.
-
Pediatric Game Changers*: Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2022 12; 87(6):1468.
-
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. J Hematol Oncol. 2022 07 16; 15(1):96.
-
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 06 01; 28(11):2270-2277.
-
Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. Int J Mol Sci. 2021 Nov 02; 22(21).
-
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nat Commun. 2021 09 09; 12(1):5337.
-
Lemborexant (Dayvigo) for the Treatment of Insomnia. Am Fam Physician. 2021 02 15; 103(4):241-242.
-
Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib. Acta Derm Venereol. 2021 Jan 04; 101(1):adv00352.
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.